glp 1 agonist news Science's 2023 Breakthrough: GLP-1 Agonists Show Promise Against Obesity-Associated Disease GLP-1 Agonists in Cardiovascular Diseases:

These medicines have also yielded meaningful benefits for obese individuals who were unable to achieve adequate weight reduction through lifestyle modifications

Note: This handout should not be used as a substitute for medical advice from your health care team

Heres where GLP-1 drugs start getting interesting

And the weight loss data from the retatrutide Phase 2 trial tells one of the most compelling stories in obesity pharmacotherapy

For context, in one study of 175 people with overweight or obesity, participants taking semaglutide: Lost an average of 15 pounds (about 6% of their body weight) within three months Lost an average of 27 pounds (about 11% of their body weight) after six months Recommended lifestyle changes during GLP-1 therapy GLP-1 medications can boost weight loss by increasing satiety and reducing food cravings